Clinical trial

MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer

NCT04078269

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention Dendritic cell immunotherapy Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Antigen-specific DTH Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Control DTH Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2019-08-26

PhasePHASE1

Conditions

Non-small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

Dendritic cell immunotherapyBIOLOGICAL

Antigen-specific DTHBIOLOGICAL

Control DTHBIOLOGICAL

Sponsors & collaborators

University Hospital, Ghentlead sponsor

University Ghentcollaborator

Kom Op Tegen Kankercollaborator

Mapped research locations

GhentBelgium1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04078269 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.